Over the last few years, "GLP-1" has moved from a niche endocrinology term into everyday conversation. Understanding what a GLP-1 receptor agonist actually is — and what it does inside the body — helps put the news stories, the marketing, and the clinical realities into proportion. This article walks through the biology in plain English, and explains how these medicines are used in UK clinical practice.
What GLP-1 is in the body
GLP-1 (glucagon-like peptide-1) is what physiologists call an incretin hormone. It is released from L-cells lining the small intestine within minutes of eating. From there it travels in the bloodstream and reaches receptors in the pancreas, the brain, the stomach and elsewhere. Its job is to help the body handle a meal — signalling to the pancreas to release insulin when blood glucose rises, telling the stomach to empty a little more slowly, and communicating fullness to appetite centres in the brain.
Natural GLP-1 has one practical limitation: it is broken down very quickly by an enzyme called DPP-4, usually within a couple of minutes. That short half-life is fine for meal-by-meal signalling, but it means the natural hormone can't be used as a medicine. Drug development therefore focused on producing molecules that behave like GLP-1 but stay active in the body for hours or days.
How GLP-1 receptor agonists mimic the natural hormone
A GLP-1 receptor agonist is a medicine engineered to bind to the same receptor as natural GLP-1 but resist rapid breakdown. Some are structurally similar to native GLP-1 with small modifications; others are more heavily engineered. The point is the same: fit the receptor, trigger the same downstream signals, and last long enough to be dosed once daily or once weekly rather than continuously.
The class currently used in UK practice includes several molecules. Semaglutide is available as a weekly injection under different brand names for diabetes and for weight management, and also as a daily oral tablet (Rybelsus). Tirzepatide is a weekly injection that acts on both the GLP-1 receptor and a related receptor called GIP. Dulaglutide is another weekly GLP-1 injection used primarily in diabetes. Liraglutide is a daily GLP-1 injection with UK licences in both diabetes and weight management. Each is a distinct molecule with its own licensed indications; they are not interchangeable.
What this means for appetite, gastric emptying and blood glucose
Once the receptor is activated, several things happen at once. In the brain, particularly in areas of the hypothalamus and brainstem that govern hunger, activation reduces the drive to eat and increases satiety — the sense of being full. Patients often describe this as a quieter appetite and finishing meals earlier, sometimes without consciously trying.
In the stomach, gastric emptying slows. Food stays in the stomach a little longer, which contributes to fullness and also flattens the rise in blood glucose that follows a meal. This slowing is one reason why nausea, reflux and early satiety are the most commonly reported side effects, especially in the first weeks of treatment or after a dose increase.
In the pancreas, GLP-1 agonists stimulate insulin release — but only in a glucose-dependent way. That means insulin release goes up when blood glucose is high (after a meal, for example) and stays quiet when blood glucose is normal. They also blunt the release of glucagon, the hormone that raises blood glucose. That combination is why they help control glucose in type 2 diabetes with a low risk of hypoglycaemia when used on their own, though the risk rises if they are combined with insulin or sulfonylureas.
How GLP-1 medicines are used in UK clinical practice
UK licensing distinguishes carefully between different indications and different molecules. Some GLP-1 receptor agonists are licensed for type 2 diabetes; some are additionally licensed for weight management in adults meeting specific BMI thresholds, usually with weight-related comorbidities. The exact wording of the licence, the eligible BMI, and any additional criteria are set out by the MHRA and reflected in the BNF and NICE guidance. A clinician prescribes within the terms of the licence and the local access pathway.
Dosing typically follows a slow titration schedule. Starting doses are deliberately low, with step-ups every few weeks to help the body adjust and reduce gastrointestinal side effects. Full "maintenance" doses are reached after several months, not weeks. Response is then reviewed over the following months — for diabetes, mainly through HbA1c and glucose readings; for weight management, mainly through weight trajectory, tolerability and any linked cardiovascular or metabolic markers.
Common side effects across the class are gastrointestinal — nausea, constipation or diarrhoea, reflux, occasional vomiting. These tend to be worst in the first days after a dose increase and usually settle. Less common but more serious concerns include acute pancreatitis, gallbladder problems and severe dehydration; these warrant urgent clinical review. Advice on injection technique, hydration, meal size and timing can make a substantial difference to how a patient tolerates treatment.
Who is and isn't typically suitable — questions to ask your clinician
GLP-1 receptor agonists are not appropriate for everyone. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, previous pancreatitis, active severe gastrointestinal disease, and pregnancy or plans for pregnancy are among the situations that need careful review before treatment is considered. People with type 1 diabetes, diabetic ketoacidosis or severe renal or hepatic impairment need particular caution. Any current medication list — especially other diabetes medicines, oral therapies with narrow absorption windows, or medications for gut motility — should be reviewed for interactions.
Useful questions to bring to a consultation include: what is the licensed indication I would be treated under, what does the titration schedule look like for me, how will response be measured, what side effects should I plan for in the first weeks, and when would treatment be stopped or changed. Your clinician will advise based on your individual circumstances rather than a general rule.
Where GLP-1 fits in the wider picture
GLP-1 receptor agonists are a class of medicines, not a shortcut. Lifestyle change — food quality, physical activity, sleep, alcohol, stress — remains part of every treatment plan, both because it improves outcomes and because it protects the benefits once treatment is eventually reviewed or stopped. In UK practice, GLP-1 treatment for weight management is offered alongside structured lifestyle support, and reviewed regularly against agreed goals. If you would like to understand more about specific molecules, our related articles cover dose escalation on Mounjaro, how long Mounjaro takes to work, and the practical question of staying on a low dose of Wegovy.